PERALDO NEIA, CATERINA
 Distribuzione geografica
Continente #
NA - Nord America 689
EU - Europa 296
AS - Asia 168
OC - Oceania 4
AF - Africa 3
SA - Sud America 3
Totale 1.163
Nazione #
US - Stati Uniti d'America 682
CN - Cina 115
IT - Italia 85
IE - Irlanda 46
SE - Svezia 27
FI - Finlandia 23
FR - Francia 23
VN - Vietnam 22
DE - Germania 21
BE - Belgio 20
PL - Polonia 14
GB - Regno Unito 12
KR - Corea 12
UA - Ucraina 8
CA - Canada 7
RU - Federazione Russa 6
AU - Australia 4
IN - India 4
NL - Olanda 4
SG - Singapore 3
CH - Svizzera 2
CL - Cile 2
ES - Italia 2
ID - Indonesia 2
JP - Giappone 2
NG - Nigeria 2
UZ - Uzbekistan 2
BR - Brasile 1
BT - Bhutan 1
GR - Grecia 1
IR - Iran 1
MY - Malesia 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
TR - Turchia 1
TW - Taiwan 1
Totale 1.163
Città #
Chandler 137
Beijing 60
Fairfield 49
Dublin 46
Ann Arbor 39
Ashburn 38
Houston 38
Woodbridge 30
Seattle 25
Nyköping 22
Torino 22
Brussels 20
Cambridge 20
Dearborn 20
Pisa 20
Dong Ket 17
Villeurbanne 17
Wilmington 17
Medford 15
Warsaw 14
Princeton 13
Shanghai 13
Munich 11
Jacksonville 8
Turin 8
Chengdu 5
Hangzhou 5
Nanjing 5
Guangzhou 4
Milan 4
New York 4
Phoenix 4
Toronto 4
Boston 3
Edinburgh 3
Abuja 2
Bengaluru 2
Capriate San Gervasio 2
Cuneo 2
Fremont 2
Hefei 2
Menlo Park 2
Ningbo 2
Québec 2
San Michele Mondovì 2
Tula 2
Abbiategrasso 1
Barcelona 1
Bern 1
Blackpool 1
Boardman 1
Bratislava 1
Buffalo 1
Burlington 1
Canberra 1
Charlotte 1
Chicago 1
Civitavecchia 1
Columbus 1
Farmington 1
Fort Wayne 1
Franklin 1
Freiburg 1
Gaithersburg 1
Genova 1
Jakarta 1
Jiaxing 1
Jinan 1
Kharkov 1
Kunming 1
La Jolla 1
Latrobe 1
Littleton 1
London 1
Maastricht 1
Madrid 1
Montréal 1
Mount Kisco 1
Mountain View 1
Muttenz 1
Naaldwijk 1
Nanchang 1
Norwalk 1
Orlando 1
Paris 1
Portland 1
Redmond 1
Redwood City 1
Reston 1
Rochester 1
Salt Lake City 1
San Mateo 1
Santa Cruz 1
Shaan 1
Shenyang 1
Sydney 1
Tabriz 1
Taipei 1
Tianjin 1
Tokyo 1
Totale 836
Nome #
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer 149
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma 142
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 137
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. 115
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 115
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas 101
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 80
Antitumor activity of Src inhibitor Saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. 77
Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. 74
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient 71
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. 68
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 57
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT) 14
Totale 1.200
Categoria #
all - tutte 3.071
article - articoli 0
book - libri 0
conference - conferenze 348
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.419


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201992 0 0 0 0 0 0 0 15 5 21 38 13
2019/2020189 8 12 8 30 14 27 25 16 9 23 13 4
2020/2021112 7 5 8 9 2 10 8 7 11 12 3 30
2021/2022174 11 14 8 14 4 1 6 5 0 12 60 39
2022/2023307 36 37 7 34 19 77 22 13 29 9 20 4
2023/202496 16 27 6 9 6 15 4 13 0 0 0 0
Totale 1.200